An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders

Ashton, Nicholas J; Hye, Abdul; Rajkumar, Anto P; Leuzy, Antoine; Snowden, Stuart; Su�rez-Calvet, Marc; Karikari, Thomas K; Sch�ll, Michael; Joie, Renaud La; Rabinovici, Gil D; H�glund, Kina; Ballard, Clive; Hortob�gyi, Tibor; Blennow, Kaj; Svenningsson, Per; Zetterberg, Henrik; Aarsland, Dag

Abstract

Cerebrospinal fluid analyses and neuroimaging can identify the underlying pathophysiology at the earliest stage of some neurodegenerative disorders, but do not have the scalability needed for population screening. Therefore, a blood-based marker for such pathophysiology would have greater utility in a primary care setting and in eligibility screening for clinical trials. Rapid advances in ultra-sensitive assays have enabled the levels of pathological proteins to be measured in blood samples, but research has been predominantly focused on Alzheimer disease (AD). Nonetheless, proteins that were identified as potential blood-based biomarkers for AD, for example, amyloid-?, tau, phosphorylated tau and neurofilament light chain, are likely to be relevant to other neurodegenerative disorders that involve similar pathological processes and could also be useful for the differential diagnosis of clinical symptoms. This Review outlines the neuropathological, clinical, molecular imaging and cerebrospinal fluid features of the most common neurodegenerative disorders outside the AD continuum and gives an overview of the current status of blood-based biomarkers for these disorders.

• Journal Article Type: Article
• Acceptance Date: Nov 7, 2019
• Online Publication Date: Apr 22, 2020
• Publication Date: 2020-05
• Deposit Date: Nov 12, 2019
• Publicly Available Date: Oct 23, 2020
• Journal: Nature Reviews Neurology
• Print ISSN: 1759-4758
• Electronic ISSN: 1759-4766
• Publisher: Nature Publishing Group
• Peer Reviewed: Peer Reviewed
• Volume: 16
• Pages: 265-284
• DOI: https://doi.org/10.1038/s41582-020-0348-0
• Public URL: https://nottingham-repository.worktribe.com/output/3233277
• Publisher URL: https://www.nature.com/articles/s41582-020-0348-0
• Additional Information: Accepted: 17 March 2020; First Online: 22 April 2020; : D.A. has received research support and/or honoraria from Astra-Zeneca, GE Health, H. Lundbeck and Novartis Pharmaceuticals, and served as paid consultant for Eisai, H. Lundbeck, Heptares, Mentis Cura and Sanofi. K.B. has served as a consultant or at advisory boards for Alector, Alzheon, Biogen, CogRx, Lilly, Novartis and Roche Diagnostics, all unrelated to the work presented in this paper. H.Z. has participated in scientific advisory boards for CogRx, Roche Diagnostics, Samumed and Wave, has given lectures in symposia sponsored by Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. M.S. has served on an advisory board for Servier. All other authors declare no competing interests.